LAVA Therapeutics N.V.
LVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $26 | $42 | $91 | $109 |
| - Cash | $35 | $44 | $100 | $151 |
| + Debt | $5 | $6 | $5 | $6 |
| Enterprise Value | -$4 | $4 | -$4 | -$37 |
| Revenue | $12 | $7 | $19 | $5 |
| % Growth | 77% | -65.1% | 262.4% | – |
| Gross Profit | $12 | $3 | $19 | $5 |
| % Margin | 100% | 48.6% | 100% | 100% |
| EBITDA | -$24 | -$41 | -$31 | -$41 |
| % Margin | -196.1% | -598.8% | -158.8% | -766.6% |
| Net Income | -$25 | -$42 | -$32 | -$42 |
| % Margin | -209.6% | -618.6% | -164.5% | -791.7% |
| EPS Diluted | -0.94 | -1.57 | -1.23 | -2.14 |
| % Growth | 40.1% | -27.6% | 42.5% | – |
| Operating Cash Flow | -$20 | -$40 | $4 | -$29 |
| Capital Expenditures | -$0 | -$1 | -$1 | -$1 |
| Free Cash Flow | -$20 | -$41 | $3 | -$29 |